• Novartis agreed to acquire UK biotech Myricx Bio for up to $1.5 billion, including $1.1 billion cash upfront.
• Deal adds Myricx’s N-myristoyltransferase inhibitor payload platform for antibody-drug conjugates, targeting improved efficacy and tolerability in solid tumors.
• Myricx’s lead ADC programs target B7-H3 and HER2, expanding Novartis’s oncology pipeline in established solid-tumor targets.
• Sofinnova Partners co-led Myricx’s seed round in 2019 and backed the company through the exit.
• Transaction expected to close in H2 2026, subject to customary closing conditions, including regulatory approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sofinnova Partners SAS published the original content used to generate this news brief on July 06, 2026, and is solely responsible for the information contained therein.